Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial RepositioningGlobeNewsWire • 09/21/22
Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in GastroenterologyGlobeNewsWire • 09/20/22
Intercept Pharmaceuticals to Participate in B. Riley's PBC Symposium on August 24, 2022GlobeNewsWire • 08/18/22
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)Zacks Investment Research • 08/05/22
Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)Zacks Investment Research • 08/05/22
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/03/22
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/03/22
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022GlobeNewsWire • 07/27/22
Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory PathBenzinga • 07/08/22
Intercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.GlobeNewsWire • 07/01/22
Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022GlobeNewsWire • 06/21/22
Intercept Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBCGlobeNewsWire • 06/03/22